SPR Therapeutics to Present at Military Health System Research Symposium

CLEVELAND, OH -- (Marketwired) -- 08/16/16 -- SPR® Therapeutics, which just received FDA clearance for its SPRINT" Peripheral Nerve Stimulation (PNS) System, will present recent clinical findings at the 2016 Military Health System Research Symposium (MHSRS) in Florida today. Research scientist, Amorn Wongsarnpigoon, PhD, will review data from several studies regarding the use of percutaneous peripheral nerve stimulation for the management of acute and chronic pain. The research has been funded, in part, by grants from the United States Department of Defense and the National Institutes of Health.

"Reduced function and limited ability to perform military duties and activities of daily life because of chronic pain are significant problems for Military Personnel and Veterans," said Maria Bennett, SPR Therapeutics Founder, President and CEO. "Percutaneous PNS is a promising, non-opioid treatment for pain relief."

SPRINT is the first and only completely reversible and the least-invasive peripheral nerve stimulation system cleared to provide relief of chronic and acute pain, including post-operative and post-traumatic pain. In one study funded by the National Institutes of Health, SPRINT was associated with a 72 percent reduction in average pain in post-amputation patients.

"Opioids are frequently prescribed for pain management among the military and Veteran populations. Because of the large potential for opioid misuse in some of these individuals, the number of Veterans diagnosed with opioid addiction has increased in recent years," said Col. Steve Cohen, MD, the 2016 recipient of the MHSRS Distinguished Service Award. "Based on the outcomes to date, SPRINT has the potential to become an important non-opioid alternative for pain relief for our soldiers and Veterans."

The SPRINT PNS System includes a threadlike wire, or lead, and a small wearable stimulator. The lead is placed percutaneously, or through the skin, via a fine needle and connects externally to the wearable stimulator about the size of an Apple® watch. The SPRINT System delivers electrical stimulation through the lead, activating peripheral nerves to achieve pain relief.

The MHSRS received a record number of submissions this year. Of those submissions, just 20 percent were chosen for presentations at the symposium in Kissimmee, Florida. The MHSRS runs through August 18th.

About SPR® Therapeutics SPR Therapeutics (www.sprtherapeutics.com) has developed a proprietary percutaneous peripheral nerve stimulation platform intended to address the critical unmet need for non-opioid, less-invasive, reversible and cost-effective treatments for acute, post-operative and chronic pain.

FOR MORE INFORMATION, CONTACT:
Mark Stultz
Senior Vice President, Market Development
SPR® Therapeutics
[email protected]
612.770.0390

FOR MEDIA QUERIES, CONTACT:
Tracey Sawicki
Frontcourt PR
[email protected]
917-297-0574

Source: SPR Therapeutics

You May Also Be Interested In

• American Fusion Inc. (OTC: AMFN) Engages Lucosky Brookman LLP as Securities and Capital Markets Counsel for Planned National Exchange Uplisting
• Christyn Williams Signs with Dallas Wings After UPSHOT League Season with Greensboro Groove
• Air T, Inc. Continues Track Record of Growth in First Quarter Fiscal 2027: Crestone Completes Acquisition of Arena